Harvest Fund Management Co. Ltd Invests $132,000 in Repligen Corporation (NASDAQ:RGEN)

Harvest Fund Management Co. Ltd purchased a new stake in shares of Repligen Corporation (NASDAQ:RGEN) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,039 shares of the biotechnology company’s stock, valued at approximately $132,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its holdings in Repligen by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock worth $1,027,165,000 after buying an additional 743,815 shares during the last quarter. Champlain Investment Partners LLC raised its position in shares of Repligen by 8.6% in the 4th quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company’s stock valued at $222,176,000 after acquiring an additional 122,595 shares during the period. Conestoga Capital Advisors LLC boosted its stake in Repligen by 3.4% during the 1st quarter. Conestoga Capital Advisors LLC now owns 980,247 shares of the biotechnology company’s stock worth $124,727,000 after acquiring an additional 32,665 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in Repligen by 183.1% during the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock valued at $132,227,000 after purchasing an additional 594,189 shares during the period. Finally, New York State Common Retirement Fund grew its holdings in Repligen by 7.6% during the first quarter. New York State Common Retirement Fund now owns 625,388 shares of the biotechnology company’s stock valued at $79,574,000 after purchasing an additional 43,946 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Stock Performance

Shares of RGEN opened at $117.07 on Friday. The stock has a market capitalization of $6.58 billion, a price-to-earnings ratio of -468.26, a PEG ratio of 2.27 and a beta of 1.11. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $182.52. The firm has a fifty day simple moving average of $123.46 and a 200 day simple moving average of $136.78. The company has a current ratio of 6.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.27.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). The company had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.65%. Repligen’s revenue was up 14.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.40 EPS. Research analysts forecast that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on RGEN shares. Royal Bank Of Canada raised their price objective on Repligen from $193.00 to $204.00 and gave the stock an “outperform” rating in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and set a $180.00 price objective on shares of Repligen in a report on Monday, May 5th. Wall Street Zen lowered Repligen from a “buy” rating to a “hold” rating in a research report on Sunday, June 29th. Stephens upgraded shares of Repligen to an “overweight” rating and set a $160.00 target price on the stock in a report on Tuesday, July 22nd. Finally, Canaccord Genuity Group reduced their price target on shares of Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a report on Wednesday, April 16th. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $169.45.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.